Studies on the dissociation of botulinum neurotoxin type A complexes

Toxicon

Volumn 57, Issue 4, 2011, Pages 555-565

  Eisele, Karl Heinz ^a   Fink, Klaus ^a   Vey, Martin ^a   Taylor, Harold V ^a  

^a MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

Botox; Botulinum neurotoxin complex; Dissociation; Dysport; Xeomin

Indexed keywords

BOTULINUM TOXIN A;

ANALYTIC METHOD; ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; COMPLEX FORMATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISSOCIATION; MOLECULAR STABILITY; PH MEASUREMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SUCROSE GRADIENT; TOXIN ANALYSIS;

BOTULINUM TOXINS, TYPE A; HYDROGEN-ION CONCENTRATION; PHARMACEUTICAL PREPARATIONS; PROTEIN MULTIMERIZATION; SODIUM CHLORIDE;

BACTERIA (MICROORGANISMS); CLOSTRIDIUM BOTULINUM; MAMMALIA;

EID: 79952364126     PISSN: 00410101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxicon.2010.12.019     Document Type: Article

References (33)

1. Benecke R., Jost W.H., Kanovsky P., Ruzicka E., Comes G., Grafe S. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 2005, 64:1949-1951.
2. Bhidayasiri R., Truong D.D. Expanding use of botulinum toxin. J. Neurol. Sci. 2005, 235:1-9.
3. Boroff D.A., Townend R., Fleck U., DasGupta B.R. Ultracentrifugal analysis of the crystalline toxin and isolated fractions of Clostridium botulinum type A. J. Biol. Chem. 1966, 241:5165-5167.
4. Brin M.F. Basic and clinical aspects of BOTOX. Toxicon 2009, 54:676-682.
5. Carli L., Montecucco C., Rossetto O. Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg. Muscle Nerve 2009, 40:374-380.
6. Carruthers A., Carruthers J. Update on the botulinum neurotoxins. Skin Therapy Lett. 2001, 6:1-2.
7. Carruthers A., Carruthers J. Botulinum toxin products overview. Skin Therapy Lett. 2008, 13:1-4.
8. Chapman M.A., Barron R., Tanis D.C., Gill C.E., Charles P.D. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia. Clin. Ther. 2007, 29:1325-1337.
9. Chen F., Kuziemko G.M., Stevens R.C. Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex species. Infect. Immun. 1998, 66:2420-2425.
10. DasGupta B.R., Boroff D.A. Separation of toxin and hemagglutinin from crystalline toxin of Clostridium botulinum type A by anion exchange chromatography and determination of their dimensions by gel filtration. J. Biol. Chem. 1968, 243:1065-1072.
11. DasGupta B.R., Boroff D.A., Rothstein E. Chromatographic fractionation of the crystalline toxin of Clostridium botulinum type A. Biochem. Biophys. Res. Commun. 1966, 22:750-756.
12. Dressler D., Saberi F.A., Barbosa E.R. Botulinum toxin: mechanisms of action. Arq. Neuropsiquiatr. 2005, 63:180-185.
13. Fu F.N., Sharma S.K., Singh B.R. A protease-resistant novel hemagglutinin purified from type A Clostridium botulinum. J. Protein Chem. 1998, 17:53-60.
14. Fujita R., Fujinaga Y., Inoue K., Nakajima H., Kumon H., Oguma K. Molecular characterization of two forms of nontoxic-nonhemagglutinin components of Clostridium botulinum type A progenitor toxins. FEBS Lett. 1995, 376:41-44.
15. Inoue K., Fujinaga Y., Watanabe T., Ohyama T., Takeshi K., Moriishi K., Nakajima H., Inoue K., Oguma K. Molecular composition of Clostridium botulinum type A progenitor toxins. Infect. Immun. 1996, 64:1589-1594.
16. Jost W.H., Kohl A., Brinkmann S., Comes G. Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers. J. Neural. Transm. 2005, 112:905-913.
17. Lietzow M.A., Gielow E.T., Le D., Zhang J., Verhagen M.F. Subunit stoichiometry of the Clostridium botulinum type A neurotoxin complex determined using denaturing capillary electrophoresis. Protein J. 2008, 27:420-425.
18. Malizio C.J., Goodnough M.C., Johnson E.A. Purification of Clostridium botulinum type A neurotoxin. Methods Mol. Biol. 2000, 145:27-39.
19. Montecucco C., Molgo J. Botulinal neurotoxins: revival of an old killer. Curr. Opin. Pharmacol. 2005, 5:274-279.
20. Niemann H. Clostridial neurotoxins-proposal of a common nomenclature. Toxicon 1992, 30:223-225.
21. Ohishi I. Oral toxicities of Clostridium botulinum type A and B toxins from different strains. Infect. Immun. 1984, 43:487-490.
22. Ohishi I., Sakaguchi G. Molecular construction of Clostridium botulinum type F progenitor toxin. Appl. Microbiol. 1975, 29:444-447.
23. Ohishi I., Sugii S., Sakaguchi G. Oral toxicities of Clostridium botulinum toxins in response to molecular size. Infect. Immun. 1977, 16:107-109.
24. Oishi I., Sakaguchi G. Purification of Clostridium botuliunum type F progenitor toxin. Appl. Microbiol. 1974, 28:923-928.
25. Roggenkamper P., Jost W.H., Bihari K., Comes G., Grafe S. Efficacy and safety of a new Botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J. Neural. Transm. 2006, 113:303-312.
26. Schantz E.J., Johnson E.A. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol. Rev. 1992, 56:80-99.
27. Schiavo G., Matteoli M., Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 2000, 80:717-766.
28. Sharma S.K., Ramzan M.A., Singh B.R. Separation of the components of type A botulinum neurotoxin complex by electrophoresis. Toxicon 2003, 41:321-331.
29. Sharma S.K., Singh B.R. Enhancement of the endopeptidase activity of purified botulinum neurotoxins A and E by an isolated component of the native neurotoxin associated proteins. Biochemistry 2004, 43:4791-4798.
30. Sugii S., Sakaguchi G. Molecular construction of Clostridium botulinum type A toxins. Infect. Immun. 1975, 12:1262-1270.
31. Wagman J., Bateman J.B. Botulinum type A toxin: properties of a toxic dissociation product. Arch. Biochem. Biophys. 1953, 45:375-383.
32. Wohlfarth K., Muller C., Sassin I., Comes G., Grafe S. Neurophysiological double-blind trial of a botulinum neurotoxin type a free of complexing proteins. Clin. Neuropharmacol. 2007, 30:86-94.
33. ® in the human EDB muscle: a double-blind, randomized, dose-ranging study. Toxicon 2008, 51:22.